Systematic identification of synergistic drug pairs targeting HIV

Nature Biotechnology

Volumn 30, Issue 11, 2012, Pages 1125-1130

  Tan, Xu ^a   Hu, Long ^b   Luquette, Lovelace J ^c   Gao, Geng ^a   Liu, Yifang ^b   Qu, Hongjing ^a   Xi, Ruibin ^c   Lu, Zhi John ^b   Park, Peter J ^c   Elledge, Stephen J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TSINGHUA UNIVERSITY   (China)

^c Harvard Medical School Center for Biomedical Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY DRUGS; COMBINATORIAL SEARCH; COMPREHENSIVE ASSESSMENT; DRUG COMBINATIONS; GLUCOCORTICOIDS; HIV INFECTION; NITAZOXANIDE; SYSTEMATIC IDENTIFICATION; US FOOD AND DRUG ADMINISTRATION;

DRUG INTERACTIONS; PATHOLOGY;

DIAGNOSIS;

ANTIINFLAMMATORY AGENT; NITAZOXANIDE; PREDNISOLONE;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DRUG COMBINATION; DRUG POTENTIATION; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MULTIPLEX SCREENING FOR INTERACTING COMPOUND; PRIORITY JOURNAL; VIRUS REPLICATION;

ALGORITHMS; ANTI-HIV AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HIV; HUMANS;

EID: 84869423899     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2391     Document Type: Article

References (37)

1. Lucas, G.M., Chaisson, R.E. & Moore, R.D. Highly active antiretroviral therapy in a large urban clinic: Tisk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131, 81-87 (1999
2. Hawkins, T. Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res. 85, 201-209 (2010
3. Richman, D.D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304-1307 (2009
4. Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010
5. Jia, J. et al. Mechanisms of drug combinations: Interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128 (2009
6. Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B. & Sorger, P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006
7. Borisy, A.A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA 100, 7977-7982 (2003
8. Lehar, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659-666 (2009
9. Wilson-Lingardo, L. et al. Deconvolution of combinatorial libraries for drug discovery: Experimental comparison of pooling strategies. J. Med. Chem. 39, 2720-2726 (1996
10. Severyn, B. et al. Parsimonious discovery of synergistic drug combinations. ACS Chem. Biol. 6, 1391-1398 (2011
11. Kimpton, J. & Emerman, M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66, 2232-2239 (1992
12. Brass, A.L. et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319, 921-926 (2008
13. Bliss, C.I. The calculation of microbial assays. Bacteriol. Rev. 20, 243-258 (1956
14. Hanley, T.M. & Viglianti, G.A. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J. Virol. 85, 10834-10850 (2011
15. Russo, F.O., Patel, P.C., Ventura, A.M. & Pereira, C.A. HIV-1 long terminal repeat modulation by glucocorticoids in monocytic and lymphocytic cell lines. Virus Res. 64, 87-94 (1999
16. Andrieu, J.M. & Lu, W. Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection. BMC Med. 2, 17 (2004
17. Ulmer, A., Muller, M., Bertisch-Mollenhoff, B. & Frietsch, B. Low dose prednisolone reduces CD4+ T cell loss in therapy-naive HIV-patients without antiretroviral therapy. Eur. J. Med. Res. 10, 105-109 (2005
18. Korba, B.E. et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77, 56-63 (2008
19. Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A. & Santoro, M.G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J. Biol. Chem. 284, 29798-29808 (2009
20. Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006
21. Yeh, P., Tschumi, A.I. & Kishony, R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38, 489-494 (2006
22. Cavrois, M., De Noronha, C. & Greene, W.C. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20, 1151-1154 (2002
23. Collins, S.R., Schuldiner, M., Krogan, N.J. & Weissman, J.S. A strategy for extracting and analyzing large-scale quantitative epistatic interaction data. Genome Biol. 7, R63 (2006
24. Hazenberg, M.D. et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881-1888 (2003
25. Deeks, S.G. et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104, 942-947 (2004
26. Giorgi, J.V. et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 29, 346-355 (2002
27. Hunt, P.W. et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126-133 (2008
28. Douek, D.C., Roederer, M. & Koup, R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60, 471-484 (2009
29. Eggena, M.P. et al. T cell activation in HIV-seropositive Ugandans: Differential associations with viral load, CD4+ T cell depletion, and coinfection. J. Infect. Dis. 191, 694-701 (2005
30. Deeks, S.G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141-155 (2011
31. Chahroudi, A., Bosinger, S.E., Vanderford, T.H., Paiardini, M. & Silvestri, G. Natural SIV hosts: Showing AIDS the door. Science 335, 1188-1193 (2012
32. Malo, N., Hanley, J.A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24, 167-175 (2006
33. Kutsch, O. et al. Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob. Agents Chemother. 48, 1652-1663 (2004
34. O'Doherty, U., Swiggard, W.J. & Malim, M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74, 10074-10080 (2000
35. Butler, S.L., Hansen, M.S. & Bushman, F.D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7, 631 (2001
36. Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L. & Ideker, T. Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27, 431 (2011
37. Petraitis, V. et al. Combination therapy in treatment of experimental pulmonary aspergillosis: In vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob. Agents Chemother. 53, 2382-2391 (2009